The expenditure includes two deals, including one for $185 million to acquire Incline Therapeutics, a company developing a device to manage post-operative pain.
The other deal is for $105 million for a two-year license to market Bristol-Myers Squibb’s device to control surgical bleeding.
Incline’s patient-controlled analgesia system called IONSYS is for short-term management of acute post-operative pain.
More Articles on Anesthesia:
Anesthesia Machine Sales Expected to Increase by 2014
FDA Does Not Approve Zogenix’s Zohydro Opioid Pain Medication
Dr. Brett Anderson Named Heritage Valley Chair of Anesthesiology
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
